ClinicalTrials.gg
RecruitingNCT07268521CRYOBIUpdated Aug 31, 2026

A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab

A Phase 2 interventional study of Obinutuzumab in Cryoglobulinemic Vasculitis (CV), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 25 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Cryoglobulinemic vasculitis (CV) is a rare life threatening systemic immune-complex-mediated vasculitic syndrome. Symptoms range from arthralgia, purpura to more severe manifestations such as peripheral neuropathy, glomerulonephritis, and skin necrosis.1 CV is associated with significant morbidity and mortality. The management of non-infectious mixed CV is currently based on steroids, and anti-CD20 monoclonal antibody Rituximab (RTX). Infectious complications of immunosuppressants (IS) remain the main cause of death in CV. During the last decade, studies reported efficacy of RTX in patients with CV in 65-70% of patients as compared to 30% for other IS (azathioprine…). However, CV relapse is noted in up to 40% patients within few days to 19 months after the last RTX infusion2. Following RTX, serum levels of B lymphocyte stimulator (BLyS) significantly increased and may favour the survival of autoreactive B cell clones and relapses of CV. A recent study has shown that RTX does not reset defective early B cell tolerance checkpoints. Incomplete B cell depletion following treatment with RTX may be associated with poor clinical response.

Moreover, some patients develop a serum sickness reaction to RTX that contraindicate further use of the medication2. Thus, there are important therapeutic unmet needs in CV patients that are refractory or intolerant to RTX.

Obinutuzumab (OBZ) is a type II anti-CD20 monoclonal antibody with a glycomodified Fc, approved in 2013 for the treatment of chronic lymphocytic leukemia. Reddy et al. found that OBZ was at least 2-fold more efficient than RTX at inducing B-cell cytotoxicity in in vitro whole blood assays of patients with rheumatoid arthritis and systemic lupus erythematosus. In lupus nephritis, OBZ resulted in increased complete and partial renal responses compared with placebo when added to mycophenolate mofetil and steroids for the treatment of lupus nephritis. There is a strong rationale for using OBZ in CV. OBZ is currently used off label in CV patients intolerant to RTX and case reports pointed out its effectiveness in CV4.5. CRYOBI is the first prospective multicenter phase 2 proof-of-concept trial assessing efficacy of OBZ in CV refractory or intolerant to RTX.

02

Conditions studied

  • Cryoglobulinemic Vasculitis (CV)

Keywords

  • Cryoglobulinemic vasculitis (CV)
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,596 studies on the registry; 1,037 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Written
  3. Active mixed cryoglobulinemia vasculitis defined by:

    • a clinically active vasculitis signs with skin, joint, renal, peripheral nerve, central neurological, digestive, pulmonary
    • and/or cardiac involvement,
    • and history of positive cryoglobulinemia and/or positive Rheumatoid factor associated with low C4 complement level, and/or a monoclonal component (IgM Kappa) and/or a histological proof of vasculitis in the affected organs
  4. or intolerant to Rituximab.

    Refractory patients are defined as any of the following after a standard rituximab regimen (375 mg/m² IV weekly for 4 consecutive weeks):

    • No measurable improvement within 4-6 weeks of initiation,
    • OR \<50% improvement in the number or severity of affected organ systems at 12 weeks, or
    • OR Persistent baseline manifestations without remission or significant improvement for >12 weeks.

    Improvement: A measurable positive change in the clinical signs, symptoms, and/or functional status of the affected organ(s), compared to baseline, as assessed using the organ-specific criteria below, without fulfilling full remission requirements.

    Remission: Complete disappearance of all baseline symptoms and objective abnormalities in the affected organ(s), as defined below:

    "CRYOBI " protocol, version v1-2 of 26/08/2025 10/68 This document is the property of DRCI/AP-HP. All reproduction is strictly prohibited. Version 4.0 dated 31/05/2019

    • The skin and articular remissions are evaluated clinically (disappearance of purpura and ulcers, disappearance of arthritis, disappearance of the skin necrosis).
    • Renal remission is evaluated biologically (proteinuria \<0.5g/24h or proteinuria/creatininuria \<50 mg/mmol), and improvement of >20% if GFR \<60 mL/min/1.73 m2 at diagnosis or glomerular filtration rate ≥60ml/min/1.73m² if GFR ≥ 60 mL/min1.73 m2 at diagnosis
    • Peripheral Neurological remission is evaluated clinically (any improvement of pains and paresthesia by visual analogue scales, any stabilization or improvement of muscular testing in case of motor impairment at baseline) and electrophysiologically (stabilization or improvement of electromyogram abnormalities compared to baseline).
    • Central Neurological remission is evaluated clinically (no new neurological symptoms and stabilization or improvement of the initial presentation) and radiologically (Cerebral MRI showing no new lesions and no contrast enhancement of the initial lesions, or regression of the initial lesion)
    • Digestive remission is evaluated clinically (resolution of abdominal pain and other gastrointestinal symptoms), and by endoscopy (resolution of potential gastrointestinal lesions seen at baseline) and/or by CT scan (resolution of any abnormalities found on baseline imaging). Complete remission of all baseline abnormalities is required to define digestive remission.
    • Cardiac remission is evaluated clinically (resolution of chest pains and other cardiac events), and biologically (normalization of myocardial enzymes) and radiologically (no late gadolinium enhancement on cardiac MRI). Complete remission of all baseline abnormalities is required to define cardiac remission.

    Pulmonary remission: complete regression of the initial symptoms with no new radiological lesions and regression of all the initial lesions.

    Intolerant: Patients who experienced treatment-limiting adverse events or toxicity that required discontinuation of rituximab, despite dose modification or supportive care.

  5. negative serology within 3 months prior inclusion
  6. Negative HBs Ag test within 3 months prior inclusion. (In case of negative AgHBs and positive HBc Ab test, test must be negative; AND Hepatitis B surveillance should be started (monthly HBsAg and HBV DNA testing for the duration of the study treatment and at least every 12 weeks after treatment is discontinued for the duration of study treatment. In addition, antiviral prophylaxis should be started before the first administration of the study treatment and continued until 12 months after completion of study treatment)
  7. negative serology or negative HCV RNA if positive HCV serology within 3 months before inclusion
  8. Affiliated to National French social security system (registered or being a beneficiary of such a scheme). Patients with AME are eligible

Exclusion criteria

Exclusion Criteria:

  1. Vasculitis unrelated to cryoglobulinemia
  2. Non-active cryoglobulinemia vasculitis
  3. Treatment with cyclophosphamide or Belimumab within 3 months prior to inclusion
  4. Malignant neoplasm within the last 5 years other than carcinoma in situ of the cervix or excised basal cell, squamous cell carcinoma of the skin and low-grade hemopathy with no indication for a specific treatment.

    "CRYOBI " protocol, version v1-2 of 26/08/2025 11/68 This document is the property of DRCI/AP-HP. All reproduction is strictly prohibited. Version 4.0 dated 31/05/2019 Carcinoma in situ of the cervix and squamous cell carcinoma of the skin should have been adequately treated before inclusion in the study.

  5. Active tuberculosis, pneumocystis, cytomegalovirus or any active infection not adequately managed or considered a risk by the investigator
  6. Have a history of an anaphylactic reaction to parenteral administration of Obitunuzumab
  7. Unstable or high-risk cardiac conditions, e.g., recent (\<6 months) myocardial infarction or unstable angina, decompensated ( III-IV) heart failure, uncontrolled arrhythmias, or any cardiac condition that, in the investigator's judgment, poses an unacceptable risk with obinutuzumab infusion
  8. Pregnant or breastfeeding women, or desire to become pregnant within 30 months All women of (WOCBP) are required to have a negative pregnancy test before treatment and must agree to maintain highly effective by practicing abstinence or by using an effective method of birth control from the date of consent until 18 months after the last obinutuzumab infusion: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (Oral, Intravaginal, Transdermal); Progestogen-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner
  9. Neutrophils \< 1000/mm3 or \< 50000/mm3
  10. within 30 days prior inclusion
  11. Patients under guardianship or curatorship and protected adults or unable to consent
  12. Progressive multifocal leukoencephalopathy
  13. Participation to another interventional study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Adult patients with non-infectious active cryoglobulinemia vasculitis

    Drug: Obinutuzumab

Interventions

  • Obinutuzumab will be administered intravenously at 1000 milligrams (mg) at week 0 and week 2

06

What researchers measure

Primary outcomes

  1. Complete Clinical Response

    Remission of all affected organs involved at baseline and with corticosteroid withdrawal in the absence of severe clinical relapse

    Time frame: At 6 months

Secondary outcomes

  1. Frequency of adverse clinical events

    Frequency and severity of adverse clinical events

    Time frame: At 12 weeks

  2. Frequency of adverse clinical events

    Frequency and severity of adverse clinical events

    Time frame: At 24 weeks

  3. Frequency of adverse clinical events

    Frequency and severity of adverse clinical events

    Time frame: At 48 weeks

  4. Rates of patients with complete clinical response with corticosteroid withdrawal (prednisone at 0 mg/day), partial response, and no clinical response

    Time frame: At 12 weeks

  5. Rates of patients with complete clinical response with corticosteroid withdrawal (prednisone at 0 mg/day), partial response, and no clinical response

    Time frame: At 24 weeks

  6. Rates of patients with complete clinical response with corticosteroid withdrawal (prednisone at 0 mg/day), partial response, and no clinical response

    Time frame: At 48 weeks

  7. Rate of patients with complete renal remission

    Defined as proteinuria \< 0.5g/24h or proteinuria/creatininuria \< 50 mg/mmol, and improvement of GFR \> 20% if GFR \< 60 mL/min/1.73 m² at diagnosis or GFR \> 60 mL/min/1.73m² if GFR ≥ 60ml/min/1.73m² at diagnosis.

    Time frame: At 12 weeks

  8. Rate of patients with complete renal remission

    Defined as proteinuria \< 0.5g/24h or proteinuria/creatininuria \< 50 mg/mmol, and improvement of GFR \> 20% if GFR \< 60 mL/min/1.73 m² at diagnosis or GFR \> 60 mL/min/1.73m² if GFR ≥ 60ml/min/1.73m² at diagnosis.

    Time frame: At 24 weeks

  9. Rate of patients with complete renal remission

    Defined as proteinuria \< 0.5g/24h or proteinuria/creatininuria \< 50 mg/mmol, and improvement of GFR \> 20% if GFR \< 60 mL/min/1.73 m² at diagnosis or GFR \> 60 mL/min/1.73m² if GFR ≥ 60ml/min/1.73m² at diagnosis.

    Time frame: At 48 weeks

  10. Rate of patients without cryoglobulinemia

    Time frame: At 12 weeks

  11. Rate of patients without cryoglobulinemia

    Time frame: At 24 weeks

  12. Rate of patients without cryoglobulinemia

    Time frame: At 48 weeks

  13. Rate of patients without rheumatoid factor activity

    Time frame: At 12 weeks

  14. Rate of patients without rheumatoid factor activity

    Time frame: At 24 weeks

  15. Rate of patients without rheumatoid factor activity

    Time frame: At 48 weeks

  16. Rate of patients with normal C4 complement level

    Time frame: At week 12

  17. Rate of patients with normal C4 complement level

    Time frame: At week 24

  18. Rate of patients with normal C4 complement level

    Time frame: At week 48

  19. Rate of patients with early treatment failure

    Defined as the absence of clinical response

    Time frame: At week 4

  20. Cumulative incidence of clinical relapse (severe or non-severe)

    Defined by reappearance of a manifestation attributable to cryoglobulinemia vasculitis

    Time frame: Up to 144 weeks

  21. Cumulative incidence of severe clinical relapse

    A severe relapse is defined by the appearance or reappearance of one of the following signs: * Extensive skin necrosis with loss of substance * Specific cardiac involvement of vasculitis (documented by EKG, troponin and/or MRI) * Specific digestive impairment of vasculitis (documented by imaging and/or endoscopy) * Affection of the central nervous system specific to vasculitis (documented by cerebral MRI) * Multiple mononeuropathy clinically defined by asymmetrical motor impairment of 2 or more nerve trunks. (Documented by electromyogram) * Severe renal impairment defined as a doubling of creatinine levels from the usual value or a glomerular filtration rate according to CKD-EPI of less than 30 ml/min/1.73m2 in the absence of prior history of creatinine levels)

    Time frame: Up to 144 weeks

  22. Cumulative incidence of mild or moderate clinical relapse

    * Appearance or reappearance of purpura * Arthritis * Sensory neuropathy documented by electromyogram * Glomerulonephritis (proteinuria\>1g/24h after excluding other causes of proteinuria)

    Time frame: Up to 144 weeks

  23. Cumulative dose of prednisone

    Time frame: At week 24

  24. Cumulative dose of prednisone

    Time frame: At 48 weeks

  25. Birmingham Vasculitis Activity Score (BVAS) activity score variation

    Standardized clinical tool used to quantify disease activity. It varies from 0 to 63. The higher the BVAS, the more active and severe the vasculitis. Variation assessed from baseline

    Time frame: Up to 12 weeks

  26. Birmingham Vasculitis Activity Score (BVAS) activity score variation

    Standardized clinical tool used to quantify disease activity. It varies from 0 to 63. The higher the BVAS, the more active and severe the vasculitis. Variation assessed from baseline

    Time frame: Up to 24 weeks

  27. Birmingham Vasculitis Activity Score (BVAS) activity score variation

    Standardized clinical tool used to quantify disease activity. It varies from 0 to 63. The higher the BVAS, the more active and severe the vasculitis. Variation assessed from baseline

    Time frame: Up to 48 weeks

  28. Variation in physical summary components of score SF-36

    SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.

    Time frame: Up to 24 weeks

  29. Variation in physical summary components of score SF-36

    SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.

    Time frame: Up to 48 weeks

  30. Variation in mental summary components of score SF-36

    SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.

    Time frame: Up to 24 weeks

  31. Variation in mental summary components of score SF-36

    SF-36 assesses overall health-related quality of life across multiple domains. Each domain is scored from 0 to 100. 0 = worst possible health status 100 = best possible health status It is assessed from baseline.

    Time frame: Up to 48 weeks

  32. Cumulative incidence of infections (severe or non-severe)

    From baseline

    Time frame: Up to 48 weeks

  33. Cumulative incidence of severe infections

    From baseline Severe infection defined by: * Tuberculosis, pneumocystis, or cytomegalovirus, * Leading to hospitalization * Leading to life threatening or death \- Progressive multifocal leukoencephalopathy. * If PML is confirmed, study agent should be discontinued and consideration should be given to stopping immunosuppressant therapy. * Neoplasia * Serious Hypersensitivity or Infusion Reactions ≥ grade 3 CTCAE * Clinically significant, potentially life-threatening (Grade 4) adverse event (AE) that the investigator believes is definitely, possibly or probably related to study agent.

    Time frame: Up to 48 weeks

  34. Cumulative incidence of non-severe infections

    From baseline Infections that do not meet the definition of a "severe infection"

    Time frame: Up to 48 weeks

  35. Cumulative incidence of non-infectious complications (cancer, lymphoma, cardiovascular event: stroke, myocardial infarction, renal replacement, …)

    From baseline

    Time frame: Up to 48 weeks

  36. Variation of gammaglobulin and of CD19+ B cells levels

    From baseline

    Time frame: Up to 12 weeks

  37. Variation of gammaglobulin levels

    From baseline

    Time frame: Up to 24 weeks

  38. Variation of gammaglobulin levels

    From baseline

    Time frame: Up to 48 weeks

  39. Overall survival

    From baseline

    Time frame: Up to 144 weeks

  40. Variation of CD19+ B cells levels

    From baseline

    Time frame: Up to 24 weeks

  41. Variation of CD19+ B cells levels

    From baseline

    Time frame: Up to 48 weeks

07

Study locations

23 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 5, 2025
StartActual
Jan 30, 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Sep 30, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07268521
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Jan 30, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

David Saadoun, MD PhD
Contact
david.saadoun@aphp.fr
+33 (0)1 42 17 80 42 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion